Navigation Links
Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
Date:1/5/2011

RESEARCH TRIANGLE PARK, N.C., Jan. 5, 2011 /PRNewswire/ -- Max Neeman announces the grant of ISO 27001:2005 certificate; one of only a few Indian CROs to be certified for Information Security.  

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

This updated certification of the world renowned British Standard for Information Security Management Systems (BS 7799-2:2002) is the standard outlining requirements for an Information Security Management System (ISMS). An ISMS helps in designing; implementing and maintaining a set of processes and systems to manage the risk posed to the information assets of an organization. Thus, helps in achieving the standards of – confidentiality, integrity and availability necessary for information security.

India is the hub of outsourced clinical research and this growth can be impeded by the threat posed to the security of the data generated in the trials. Sponsor companies have been seen to be apprehensive about information security.  

Max Neeman is involved in the development of various novel research molecules and handles crucial information related to the development of these molecules. ISO 27001 certification assures that the systems, processes and controls are rigorous to protect the integrity and confidentiality of information.  The certification helps Max Neeman in assuring the clients on integrity and confidentiality of the data generated in clinical research.  

The ISO 27001:2005 certification Max Neeman has achieved, assures that systems, processes and controls are stringent and sound enough to protect the integrity and confidentiality of information. Max Neeman is in par with all the other global Contract Research Organizations and in meeting global standards.

About Max Neeman International

Max Neeman International is a leading India-based CRO. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
2. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
5. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
6. Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
7. Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. Bacterin International Holdings to Present at the OneMedForum San Francisco 2011
11. SRI International Completes Integration of Sarnoff Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):